Fluorine-18-Fluoroethylcholine PET/CT in the detection of prostate cancer: A South African experience

Hellenic Journal of Nuclear Medicine

Volumn 18, Issue 1, 2015, Pages 53-59

  Vorster, Mariza ^a   Modiselle, Moshe ^a   Ebenhan, Thomas ^a   Wagener, Carl ^b   Sello, That ^b   Zeevaart, Jan Rijn ^a,b   Moshokwa, Evelyn ^a   Sathekge, Mike Machaba ^a  

^a STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^b NECSA   (South Africa)

Author keywords

PET CT Fluoroethylcholine; Prostate cancer

Indexed keywords

FLUOROETHYLCHOLINE F 18; FUROSEMIDE; IOPROMIDE; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; FLUORINE; FLUOROETHYLCHOLINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER STAGING; CAUCASIAN; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; EARLY CANCER; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MALE; MEDIASTINUM LYMPH NODE; PELVIS CANCER; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; STANDARDIZED UPTAKE VALUE; STATISTICAL ANALYSIS; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; ETHNOLOGY; IMAGE PROCESSING; METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; PROSTATE TUMOR; QUALITY CONTROL; RADIOGRAPHY; SCINTISCANNING;

AFRICAN AMERICANS; AGED; CHOLINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY CONTROL; RADIOPHARMACEUTICALS; SOUTH AFRICA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84927126066     PISSN: 17905427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Demers RY, Swanson GM, Weiss LK, Kau TY. Increasing incidence of cancer of the prostate, the experience of black and white men in the Detroit metropolitan area. Arch Intern Med 1994; 154: 1211-6.
2. Isaacs WB, Bova GS, Morton RA et al. Molecular genetics and chromosomal alterations in prostate cancer. Cancer 1995; 75: 2004-12.
3. Hsing AW, Yeboah E, Biritwum R et al. High Prevalence of Screen Detected Prostate Cancer in West Africans: Implications for Racial Disparity of Prostate Cancer. J Urol 2014; 192: 730-6.
4. Tindall E, Monare R, Petersen DC et al. Clinical Presentation of Prostate Cancer in Black South Africans. The Prostate 2014; 74: 880-91.
5. Jadvar H. Prostate Cancer: PET with 18F-FDG, 18F-or 11C-Acetate, and 18F or 11C-Choline. J Nucl Med 2011; 52: 81-9.
6. Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am 2003; 30: 219-26.
7. Tolonen TT, Kujala PM, Tammela TLJ et al. Overall and worst gleason scores are equally good predictors of prostate cancer progression. BMC Urol 2011; 11: 21.
8. Jadvar H, Alavi A. Role of imaging in prostate cancer. PET Clin 2009; 4: 135-8.
9. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34: 274-92.
10. Picchio M, Messa C, Landoni C et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: A comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169: 1337-40.
11. Jana S, Blaufox M, Nuclear Medicine Studies of the Prostate, Testes, and Bladder. Semin Nucl Med 2006; 36: 51-72.
12. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 6: 1471-4.
13. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18Ffluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006; 36: 73-92.
14. Schiavina R, Scattoni V, Castellucci P, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymphnode staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54: 392-401.
15. Testa C, Schiavina R, Lodi R et al. Prostate cancer: sextant localization with MRimaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007; 244: 797-806.
16. Häcker A, Jeschke S, Leeb K et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: com-parison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006; 176: 2014-8.
17. Scher B, Seitz M, Albinger W et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34: 45-53.
18. Zheng QH, Gardner TA, Raikwar S et al. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem 2004; 12: 2887-93.
19. Evangelista L, Zattoni F, Guttilla A et al. Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer. A Systematic Review and Meta-Analysis. Clin Nucl Med 2013; 38: 305-14.
20. Schmaljohann J, Schirrmacher E, Wängler B et al. Fully automated SPE-based synthesis and purification of 2-[18F]fluoroethyl-choline for human use. Nucl Med and Biol 2011; 38: 165-70.
21. Polednak AP. Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race. Cancer 1992; 79: 2152-8.
22. Guo Y, Sigman DB, Borkowski A, Kyprianou N. Racial differences in prostate cancer growth: Apoptosis and cell proliferation in Caucasian and Africa American patients. The Prostate 2000; 42: 130-6.
23. Whittemore AS, Ross RK. Why do African-American men suffer more prostate cancer? J Natl Cancer Inst 1997; 889: 188-9.
24. Walker AR, Walker B F, Tsotetsi NG et al. Case-control study of prostate cancer in black patients in Soweto, South Africa. Br J Cancer 1992; 65: 438-41.
25. Patel AR, Jones JS, Rabets J et al. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. Urology 2004; 63: 87-9.
26. Mazzucchelli R, Scarpelli M, Cheng L et al. Pathology of prostate cancer and focal therapy ('male lumpectomy'). Anticancer Res 2009; 29: 5155-61.
27. Bantis A, Grammaticos P. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased? Hell J Nucl Med 2012; 15(3): 241-6.
28. Chondrogiannis S, Marzola MC, Ferretti A et al. Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40: 1356-64.
29. Bantis A, Zissimopoulos A, Kalaitzis S et al. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment. Hell J Nucl Med 2008; 11(1): 21-5.
30. Zafeirakis A. Scoring systems of quantitative bone scanning in prostate cancer: historical overview, current status and future perpsectives. Hell J Nucl Med 2014; 17(2): 136-44.
31. Zissimopoulos A, Bantis A, Sountoulides P et al. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. Hell J Nucl Med 2009; 12(3): 234-7.
32. Boorjian SA, Karnes RJ, Rangel LJ et al. Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179(4): 1354-60.
33. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in Oncology. Prostate Cancer, version I.2014. NCCN.org [Access date March 2014].
34. Cooperberg MR, Pasta DJ, Elkin EP et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173(6): 1938-42. Erratumin: J Urol 2006; 175(6): 2369.
35. Heidenreich A1, Bastian PJ, Bellmunt J et al. EAU guidelines onprostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65(1): 124-37.
36. Hricak H, Choyke PL, Eberhardt SC et al. Imaging prostate cancer: a multidisciplinary perspective. Radiol 2007; 243: 28-53.
37. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34: 274-92.
38. Picchio M, Messa C, Landoni C et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: A comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169: 1337-40.
39. Pelosi E, Arena V, Skanjeti A et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008; 113: 895-904.
40. Breeuwsma AJ, Pruim J, Jongen MM et al. In vivo uptake of [11C] choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005; 32: 668-73.
41. Fuccioa C, Castelluccia P, Schiavinab R et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol 2012; 81: 893-6.
42. Husarik DB, Miralbell R, Dubs M et al. Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 253-63.
43. Soyka JD, Muster MA, Schmid DT et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2012; 39: 936-43.
44. Graute V, Jansen N, Übleis C, Seitz M et al. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39: 271-82.